TY  - JOUR
AU  - Castellano, Daniel
AU  - Maroto, José Pablo
AU  - Espinosa, Enrique
AU  - Grande, Enrique
AU  - Bolós, M Victoria
AU  - Llinares, Julia
AU  - Esteban, Emilio
AU  - González Del Alba, Aranzazu
AU  - Climent, Miguel Angel
AU  - Arranz, Jose Angel
AU  - Méndez, Mª José
AU  - Fernández Parra, Eva
AU  - Antón-Aparicio, Luis
AU  - Bayona, Cristina
AU  - Gallegos, Isabel
AU  - Gallardo, Enrique
AU  - Samaniego, Luz
AU  - García Donas, Jesús
PY  - 2017
DO  - 10.1080/14740338.2017.1330410
UR  - http://hdl.handle.net/10668/11225
T2  - Expert opinion on drug safety
AB  - A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. To evaluate the effectiveness and safety of sunitinib in patients with...
LA  - en
KW  - Effectiveness
KW  - routine clinical practice
KW  - safety
KW  - sunitinib
KW  - Angiogenesis Inhibitors
KW  - Antineoplastic Agents
KW  - Carcinoma, Renal Cell
KW  - Disease-Free Survival
KW  - Humans
KW  - Indoles
KW  - Kidney Neoplasms
KW  - Neoplasm Metastasis
KW  - Pyrroles
KW  - Randomized Controlled Trials as Topic
KW  - Spain
KW  - Sunitinib
KW  - Survival Rate
KW  - Treatment Outcome
TI  - Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
TY  - research article
VL  - 17
ER  -